Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 23, 2015 12:38 AM ET


Company Overview of Advanced Accelerator Applications S.A.

Company Overview

Advanced Accelerator Applications S.A., a radiopharmaceutical company, develops, produces, and commercializes molecular nuclear medicine (MNM) diagnostic and therapeutic products in France, Italy, Spain, Israel, Canada, the United States, and internationally. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of serious medical conditions primarily in oncology through assessing glucose metabolism; IASOflu, which images bone metastases; IASOdopa to diagnose Parkinson’s disease and tumors in various indications; and IASOcholine for diagnosing prostate cancer. The company also offers single-...

20 Rue Diesel

Saint Genis Pouilly,  01630


Founded in 2002

324 Employees


33 4 50 99 30 70


33 4 50 99 30 71

Key Executives for Advanced Accelerator Applications S.A.

Founder, Chief Executive Officer, President, Director and Member of R & D Steering Committee
Age: 48
Group Chief Financial Officer
Age: 51
Chief Operating Officer
Age: 56
Head of Clinical Development
Age: 59
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Advanced Accelerator Applications S.A. Key Developments

Advanced Accelerator Applications S.A. Presents at BioEquity Europe 2015, May-19-2015 05:40 PM

Advanced Accelerator Applications S.A. Presents at BioEquity Europe 2015, May-19-2015 05:40 PM. Venue: InterContinental Vienna, Vienna, Austria.

Advanced Accelerator Applications S.A. Presents at BIO-Europe Spring 2015, Mar-09-2015

Advanced Accelerator Applications S.A. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Advanced Accelerator Applications S.A. Announces Earnings Results for the First Nine Months of 2014

Advanced Accelerator Applications S.A. announced earnings results for the first nine months of 2014. For the nine months, sales of EUR 50,156,000 compared to EUR 38,919,000 a year ago. Operating income was EUR 2,199,000 compared to EUR 1,373,000 a year ago. Net income from continuing operations was EUR 1,135,000 compared to loss of EUR 2,038,000 a year ago. Adjusted EBITDA was EUR 9,668,000 compared to EUR 7,643.000 a year ago. Net operating cash-flow was EUR 9 million, an increase of 33% compared to the 6.7 million a year ago.

Similar Private Companies By Industry

Company Name Region
DNA Gensee Société par actions simplifiée Europe
Etablissements Ravier Touzard Europe
VenomeTech SAS Europe
Phytéov Europe
High-tech Bio Activities SA Europe

Recent Private Companies Transactions

January 8, 2015
AAA Canada

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Advanced Accelerator Applications S.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at